يستعمل دواء اليمتا 500 مجم لعلاج الاورام السرطانيةalimta 500mg i.v. vial(tender) antineoplastic antineoplastic

it is approved by the fda in combination with cisplatin (another chemotherapy drug) for the initial treatment of advanced nonsquamous non-small cell lung cancer (nsclc) a specific type of nsclc. it is not indicated for patients who have a different type of nsclc called squamous cell. - -it is approved by the fda for the treatment of patients with advanced nonsquamous non-small cell lung cancer (nsclc) a specific type of nsclc to maintain the effect of initial treatment with chemotherapy and whose disease has not worsened. it is not indicated for patients who have a different type of nsclc called squamous cell. - -it is approved by the fda as a single agent (used alone) for the treatment of patients with advanced nonsquamous non-small cell lung cancer (nsclc) a specific type of nsclc after prior chemotherapy. it is not indicated for patients who have a different type of nsclc called squamous cell. it is a treatment for malignant pleural mesothelioma. - -dose: once every 21 days.